Diazepam (Valium) vs Stiripentol
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Epilepsy
Shared mechanism: GABA-A receptor · full Epilepsy pipeline
Diazepam (Valium)
Marketed by Waylis Therapeutics LLC and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Stiripentol
Marketed by Biocodex
NCT07176832 · Phase 1 · completed
This is an open-label pharmacokinetic bioequivalence study comparing two formulations of the same already-marketed drug in healthy volunteers, not a controlled trial measuring clinical efficacy against a comparator or placebo.
No aligned efficacy figure on record for this race.
Results for Epilepsy
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Diazepam (Valium) | Stiripentol |
|---|---|---|
| Seizure frequency, % change | —Not posted · NCT00621478 | —Not reported |
| 50% responder rate | —Not posted · NCT00621478 | —Not reported |
| Seizure freedom | —Not posted · NCT00621478 | —Not reported |
Seizure frequency, % change
- Diazepam (Valium)
- —Not posted · NCT00621478
- Stiripentol
- —Not reported
50% responder rate
- Diazepam (Valium)
- —Not posted · NCT00621478
- Stiripentol
- —Not reported
Seizure freedom
- Diazepam (Valium)
- —Not posted · NCT00621478
- Stiripentol
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Stiripentol: no structured comparison results are available for Epilepsy.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Diazepam (Valium): 3 of 4 rows · Stiripentol: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Diazepam (Valium) |
|---|---|
| Dropout rate | 3.2%a NCT01417078 · Phase 2 · registry result, not featured evidence show 1 more result76.5% NCT00326612 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —a NCT01417078 · Phase 2 · registry result, not featured evidence show 1 more result— NCT00326612 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 0%a NCT01417078 · Phase 2 · registry result, not featured evidence show 1 more result0% NCT00326612 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | a headache 51.6% dysgeusia 25.8% nasal discomfort 22.6% NCT01417078 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Diazepam (Valium)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Diazepam (Valium)'s landscape · Stiripentol's landscape